TC
PSTX icon

Trium Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Trium Capital’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-386,407
Closed -$3.71M – 61
2024
Q4 		$3.71M Buy
+386,407
New +$2.02M 0.53% 9

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Trium Capital's PSTX Position: Q1 2025 in Review

Trium Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 386,407 shares — an estimated $3.71M sold.

Trium Capital first reported a position in PSTX in Q4 2024 and held it in 1 quarter. The position peaked at $3.71M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Trium Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Trium Capital sold 386,407 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $3.71M.
  • Trium Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
  • Trium Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $3.71M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Trium Capital's 13F filing for Q1 2025, filed 30 Apr 2025.